<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1024">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147818</url>
  </required_header>
  <id_info>
    <org_study_id>SSA</org_study_id>
    <nct_id>NCT05147818</nct_id>
  </id_info>
  <brief_title>Risk Factors for Acute Kidney Injury in Diabetic Patients</brief_title>
  <official_title>Risk Factors for Acute Kidney Injury in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      incidence of AKI in diabetic patients seems to be influenced by multiple risk Factors like&#xD;
      severe infections, elderly, poor diabetic control, previous AKI, chronic kidney disease and&#xD;
      drugs like SGLT2-I increase risk of AKI in diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence and prevalence of diabetes mellitus (DM) have increased over the last 20 years.&#xD;
      The defining feature of diabetes mellitus (DM) is the presence of hyperglycaemia . mostly due&#xD;
      to the progressively increasing prevalence of obesity and the metabolic syndrome, Current&#xD;
      prevalence of DM worldwide is estimated to be about 390 million people . The Cardiovascular&#xD;
      complications increase morbidity and mortality in diabetic patients. About 40% of end-stage&#xD;
      renal disease on regular dialysis are diabetic . Acute kidney injury (AKI) Is a fundamental&#xD;
      problem in hospitalized patients; its incidence has been reaching 20% in middle-Europe .&#xD;
      About 50% of patients presented with AKI are found to be diabetic ; which may indicate a&#xD;
      direct relationship between the two conditions. In 2012, a clinical practice guideline&#xD;
      published by Kidney Disease: Improving Global Outcomes (KDIGO) provided a unifying definition&#xD;
      and staging system for AKI . On the other hand, incidence of AKI in diabetic patients seems&#xD;
      to be influenced by multiple risk Factors like severe infections, elderly, poor diabetic&#xD;
      control, previous AKI, chronic kidney disease and drugs like SGLT2-I increase risk of AKI in&#xD;
      diabetic patients. We aim in this study to identify the most common risk factors for AKI in&#xD;
      diabetic patients and how those risk factors affect morbidity and mortality in patients with&#xD;
      DM who developed AKI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify risk factors for Acute kidney injury in diabetic patients</measure>
    <time_frame>2 years</time_frame>
    <description>Identify risk factors for Acute kidney injury in d iabetic patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Diabete Mellitus</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on KIDIGO Definition &amp; Staging. KDIGO definition of AKI: Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or Increase in serum creatinine to ≥1.5 times baseline that is known or presumed to have occurred within the prior 7 days, or Urine volume &lt;0.5 mL/kg/h for 6 h.&#xD;
KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or ≥0.3 mg/dL (≥26.5 µmol/L) increase / Urine output &lt;0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine 2.0-2.9 × baseline / Urine output &lt;0.5 mL/kg/h for ≥12 h (3) stage 3: Serum creatinine 3.0 × baseline, increase in serum creatinine to ≥4.0 mg/dL (≥353.6 µmol/L), initiation of renal replacement therapy, or, in patients &lt;18 years, decrease in eGFR to &lt;35 mL/min per 1.73 m2 / Urine output &lt;0.3 mL/kg/h for ≥24 h or anuria for ≥12 h .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>200 Diabetic patients of 18 year and older with no AKI (either type 1or 2) Matched to controls in age ,sex</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBC ,renal function tests , fundus Examination</intervention_name>
    <description>Laboratory investigations</description>
    <arm_group_label>Cases</arm_group_label>
    <other_name>ECG</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients aged from 18 year and older Diabetic patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Inclusion criteria for the cases :&#xD;
&#xD;
        200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on&#xD;
        KIDIGO Definition &amp; Staging. KDIGO definition of AKI: Increase in serum creatinine by ≥0.3&#xD;
        mg/dL (≥26.5 µmol/L) within 48 h, or Increase in serum creatinine to ≥1.5 times baseline&#xD;
        that is known or presumed to have occurred within the prior 7 days, or Urine volume &lt;0.5&#xD;
        mL/kg/h for 6 h.&#xD;
&#xD;
        KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or ≥0.3 mg/dL (≥26.5&#xD;
        µmol/L) increase / Urine output &lt;0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine&#xD;
        2.0-2.9 × baseline / Urine output &lt;0.5 mL/kg/h for ≥12 h (3) stage 3: Serum creatinine 3.0&#xD;
        × baseline, increase in serum creatinine to ≥4.0 mg/dL (≥353.6 µmol/L), initiation of renal&#xD;
        replacement therapy, or, in patients &lt;18 years, decrease in eGFR to &lt;35 mL/min per 1.73 m2&#xD;
        / Urine output &lt;0.3 mL/kg/h for ≥24 h or anuria for ≥12 h .&#xD;
&#xD;
        Inclusion criteria for matched controls 200 Diabetic patients of 18 year and older with no&#xD;
        AKI (either type 1or 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria for cases and controls:&#xD;
&#xD;
          1. Non-Diabetic patients with AKI&#xD;
&#xD;
          2. Diabetic patients with:&#xD;
&#xD;
               -  HBS Ag, HCV, HIV&#xD;
&#xD;
               -  Active Lupus&#xD;
&#xD;
               -  Active Malignancy&#xD;
&#xD;
               -  Acute or Chronic Liver Disease&#xD;
&#xD;
               -  Acute poisoning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <reference>
    <citation>American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015 Jan;38 Suppl:S8-S16. doi: 10.2337/dc15-S005. Review.</citation>
    <PMID>25537714</PMID>
  </reference>
  <reference>
    <citation>Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. Implement Sci. 2015 Dec 15;10:172. doi: 10.1186/s13012-015-0354-6. Review.</citation>
    <PMID>26670418</PMID>
  </reference>
  <reference>
    <citation>Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complications. 2013 Sep-Oct;27(5):526-30. doi: 10.1016/j.jdiacomp.2013.03.003. Epub 2013 Apr 22. Review.</citation>
    <PMID>23619194</PMID>
  </reference>
  <reference>
    <citation>Bienholz A, Wilde B, Kribben A. From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury. Clin Kidney J. 2015 Aug;8(4):405-14. doi: 10.1093/ckj/sfv043. Epub 2015 Jul 9.</citation>
    <PMID>26251707</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5. Review.</citation>
    <PMID>33547417</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 27, 2021</last_update_submitted>
  <last_update_submitted_qc>November 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shimaa Salah Ali</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

